Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Telemedycyna Polska's EBITDA for the
three
months ended in Mar. 2026 was zł0.03 Mil. Telemedycyna Polska's Revenue for the
three
months ended in Mar. 2026 was zł1.43 Mil. Therefore, Telemedycyna Polska's EBITDA margin for the quarter that ended in Mar. 2026 was 1.75%.
Telemedycyna Polska (WAR:TMP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Telemedycyna Polska EBITDA Margin % Related Terms
Telemedycyna Polska EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Telemedycyna Polska's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:TMP vs VEEV, BTSG, HQY: EBITDA Margin % Comparison
For the Health Information Services subindustry, Telemedycyna Polska's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telemedycyna Polska EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Telemedycyna Polska's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Telemedycyna Polska's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telemedycyna Polska (WAR:TMP) has a EBITDA Margin % of 1.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Telemedycyna Polska and its competitors. According to the industry distribution chart, Telemedycyna Polska ranks #549 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 82.8%.
Is Telemedycyna Polska's EBITDA Margin % too high?
Telemedycyna Polska's current EBITDA Margin % is 1.75%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. Telemedycyna Polska's value of 1.75% is 82.9% below this industry median. Based on the distribution chart, Telemedycyna Polska ranks #549 out of 663 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Telemedycyna Polska has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telemedycyna Polska's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Telemedycyna Polska ranks #549 out of 663 companies for EBITDA Margin %. This places Telemedycyna Polska in the lower half of its industry. The industry median EBITDA Margin % is 10.23. Telemedycyna Polska's value of 1.75% is 82.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telemedycyna Polska's current EBITDA Margin % of 1.75% is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Telemedycyna Polska and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telemedycyna Polska's current EBITDA Margin % is 1.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telemedycyna Polska stock overvalued right now?
Based on GuruFocus' analysis, Telemedycyna Polska (WAR:TMP) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.82, compared to a current price of zł0.65 — trading 20.7% below its estimated fair value. The current EBITDA Margin % is 1.75% and 82.9% below the Healthcare Providers & Services industry median of 10.23. Telemedycyna Polska's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Telemedycyna Polska (WAR:TMP), the current EBITDA Margin % is 1.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telemedycyna Polska (WAR:TMP) Overvalued in 2026?
Based on GuruFocus' analysis, Telemedycyna Polska stock appears to be undervalued.
The current stock price of zł0.65 is trading 20.7% below its estimated GF Value™ of zł0.82.
GuruFocus considers Telemedycyna Polska to be Modestly Undervalued.
Key valuation signals for WAR:TMP:
EBITDA Margin %: 1.75%
GF Value™: zł0.82 vs. price of zł0.65 (20.7% below fair value)
Industry Position: 82.9% below the Healthcare Providers & Services median (#549 of 663)
No single metric tells the full story. See the WAR:TMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telemedycyna Polska SA offers telecardiology services for individual patients and medical facilities in Poland. The company offers cardiologic care services through telephone and Internet. The company also provides telemedical services to health centres.
28GF Score
Get the complete analysis for WAR:TMP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:TMP has been successfully added to your 
